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From: Medical Conspiracy Theories and Health Behaviors in the United States
JAMA Intern Med. 2014;():. doi:10.1001/jamainternmed.2014.190
Vaccine Attitudes, Concerns, and Information Sources 
Reported by Parents of Young Children: Results from the 2009 
HealthStyles Survey
Kennedy, Basket, & Sheedy. Pediatrics 127(S1): S92-99 (2011)
93.4% Reported children receiving vaccine
79.8% Believed vaccines important to child health
79.0% Confident about vaccine safety
Effective Messages in Vaccine Promotion: A Randomized Trial
Nyhan et al., Pediatrics 133(4): 1-8 (2014)
Tested 4 interventions:
• Lack of evidence for autism link
• Disease dangers
• Disease images
• Dramatic narrative
“decreased intent to vaccinate 
among parents who had the 
least favorable vaccine 
attitudes”
From Nature 473:436 (2011)
21st Century Prophylaxis
• Vaccine
• Manufacturing
• Vaccination
• Host Response
• Preparedness
Vaccine Directions
• Antigen discovery and selection (including in silico)
• Common epitope approaches (universal vaccines)
• Targeting organisms for which drug resistance is emerging
• Novel vaccine concepts to address chronic infectious diseases
• Passive vaccination approaches
Manufacturing Directions
• Unique and diverse expression systems (beyond an egg and 
free living organisms)
– Bacteria
– Eukaryotic cells
– Baculo- / insect lines
– Plants
– Synthetic / Cell free translation
• Disposable, large scale platforms
• Synthetic generation of agent
Vaccination Directions
• Adjuvants
– Reduce number of doses
– Reduce antigen load
– Fine tune immune response
• Stabilization
– Eliminate refrigeration requirement
– Enhance shelf life
– Enable novel packaging and devices
• Alternative delivery devices
– Reduce trained health care worker need
– Increase compliance 
– Improve throughput
Host Response Directions
• Murine immune system is at best a very crude model of human 
immunity (concomitantly, murine pathogenesis is an even 
cruder approximation of human disease)
• Animal models are focusing on identification of correlates and 
even true immunological surrogates
• Immunity is more than neutralizing antisera
• Improved assessment tools for human immune status and 
responses
Ancillary Issues
• Discovery, characterization, and validation of biomarkers for 
immune status
• Clinical endpoints
• Robust, reproducible cellular assays
• In vitro / ex vivo predictive systems
• Utilization of “correlates” versus “a correlate”







Erica Saphire, Scripps Research Institute
Selected efforts underway:
• Characterize virus
• Improve diagnostic specificity
• Test antivirals
• Develop animal models
• Natural history studies
• Evaluate the Zika & dengue interface
• Develop vaccine
Preparedness
• Emerging infectious diseases present unique challenges
• Surveillance systems are crude and limited
• Conduct of research is difficult even under optimal conditions
• Existing regulatory frameworks are not optimal for outbreaks
What do we need to prepare for?
(with apologies to Donald Rumsfeld)
• Expected knowns
– Pandemic Influenza
• Unexpected knowns
– Ebola (or any filovirus)
• Unknown knowns
– Zika
• Unknown unknowns
– ???
Expected knowns (flu)
• History suggests this can and will occur
• Experience with similar vaccines allows for straightforward 
(although not necessarily simple or easy) vaccine development 
in a timeline that can potentially align with the outbreak
• Existing infrastructure can be co-opted for development
• Safety will always be an issue
– Dose and regimen
– Special populations
Unexpected knowns (Ebola)
• Even with extensive microbiological and pathogenesis 
information, socioeconomic / cultural factors can dramatically 
impact disease transmission and severity
• New clinical experience may alter prevention & treatment
• Exogenous factors such as climate change, urban versus rural 
population centers, greater local and distant mobility, varying 
degrees of public health infrastructure, etc. 
• Variable degrees of development efforts will need increased 
resources and streamlining
Unknown knowns (Zika)
• Extremely difficult to be prepared, mostly due to a long list of 
agents that have been identified with higher priority
• Need to rely on expert panels to identify candidate lists 
(pandemic / epidemic wanna-be’s)
• Likely need to be already working on vaccine candidates to 
impact future outbreaks
• Pandemic / epidemic potential may evolve to endemic
• Resource limitations major impediment
For Consideration
• WHO Workshop on Prioritization of Pathogens (12/8-9/2015)
– Urgent
• Crimean-Congo hemorrhagic fever
• Filoviruses (EVD & Marburg)
• Highly pathogenic emerging Coronaviruses (MERS Co-V & SARS)
• Lassa Fever
• Nipah
• Rift Valley Fever
– Serious
• Chikungunya
• Severe Fever with Thrombocytopenia Syndrome
• Zika 
So what’s an unknown unknown?
• Basically, something we’ve never seen before
• Little precedence with known infectious agents
• No information regarding natural immunity
• Sparse human pathogenesis
• Limited information from animal models
• Initially, mostly sequence information
• How can we be prepared?

Zombie Threat Summary
• Pathogenic zombies (PZ)
• PZs are zombie life forms created after an 
organism is infected by a virus or bacteria or 
some other form of contagion
• Radiation zombies
• Evil Magic zombies
• Space zombies
• Weaponized zombies
• Symbiant-Induced zombies
• Vegetarian zombies
• Chicken zombies

Moving Faster
• Initiate early development on experts’ derived lists
• Don’t wait for specimens; work from sequences
• Platform selection for ease of candidate selection & manufacturing
– Several vaccine manufacturers are offering proposals
• Move towards universal / broadly protective responses
• Rate limiting issues:
– Sequence breadth
– Animal models
– Assay development
– Clinical trial capacity in theater
Possible additional considerations
• Broad spectrum antivirals
• Passive vaccination / prophylaxis
Questions?
